News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Vical Incorporated (VICL) Licenses DNA Immunization Technology and Vaxfectin® Adjuvant to Bristol-Myers Squibb Company (BMY) for Use in Antibody Production



9/13/2012 9:30:21 AM

SAN DIEGO, Sept. 13, 2012 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today a worldwide, nonexclusive license to Bristol-Myers Squibb Company (NYSE:BMY) of Vical's patented platform DNA immunization technology and its Vaxfectin® adjuvant for use in the production of antibodies.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES